Dr. Paul Offit - Autism's False Prophets: Bad Science, Risky Medicine, and the Search for a Cure

Paul A. Offit, MD

Paul A. Offit, MD: Resume
Office Address:	Division of Infectious Diseases Abramson Research Building, Room 1202D The Children's Hospital of Philadelphia 3615 Civic Center Blvd. Philadelphia, PA. 19104 (215) 590-2020 (215) 590-2025 (FAX) email: offit@email.chop.edu
Education:	1969-73B.S.Tufts University 1973-77M.D.University of Maryland School of Medicine
Postgraduate Training and Fellowship Appointments:
	1977-80	Intern and Resident in Pediatrics, Children's Hospital of Pittsburgh, Pittsburgh
	1980-82	Fellowship, Infectious Diseases, Children's Hospital of Philadelphia, Philadelphia
Faculty Appointments:
	1982-84	1982-84 Instructor in Pediatrics, Department of Pediatrics, University of Pennsylvania School of Medicine
	1982-85	1982-85 Research Investigator, The Wistar Institute of Anatomy and Biology
	1984-85	1984-85 Clinical Assistant Professor in Pediatrics, Department of Pediatrics, University of Pennsylvania School of Medicine
	1985-87	1985-87 Research Associate, Dept. of Medical Microbiology, Stanford University School of Medicine
	1986-87	1986-87 Clinical Assistant Professor, Division of Pediatric Infectious Diseases, Stanford University School of Medicine
	1987-92	1987-92 Assistant Professor, Department of Pediatrics, The University of Pennsylvania School of Medicine
	1987-92	1987-92 Assistant Professor, The Wistar Institute of Anatomy and Biology
	1992-00	Associate Professor, Department of Pediatrics The University of Pennsylvania School of Medicine
	1991-	1991- Adjunct Associate Professor, The Wistar Institute of Anatomy and Biology
	2000-	Professor, Department of Pediatrics The University of Pennsylvania School of Medicine
Hospital and Administrative Appointments
	1992-	Chief, Section of Infectious Diseases, The Children's Hospital of Philadelphia
	1992-	Chairman, Drug Use Evaluation Committee The Children’s Hospital of Philadelphia
	1994-	Chairman, Therapeutic Standards Committee The Children’s Hospital of Philadelphia
Specialty Certification:
	1982	American Board of Pediatrics
Licensure:	Pennsylvania and California
Awards, Honors, and Membership in Honorary Societies:
	1977	J. Edmund Bradley Prize for Excellence in Pediatrics, University of Maryland Medical School
	1981	Fellow's Annual Teaching Award, The Children's Hospital of Philadelphia
	1988	Lederle Young Investigator Award in Vaccine Development The University of Pennsylvania Research Foundation Award
	1991	Research Achievement Award, The Children’s Hospital of Philadelphia
	1997	Elected to the council of the Society of Pediatric Research Recipient of the Werner and Gertrude Henle Chair in Pediatric Immunologic and Infectious Diseases at the Children’s Hospital of Philadelphia
	1998	Elected to the Executive Committee of the Joseph Stokes, Jr. Research Institute
	2001	“Excellence in Service” Award from the Delaware Valley Immunization Coalition
	2003	Fellow, College of Physicians of Philadelphia
	2004	Recipient of the Maurice R. Hilleman Chair in Vaccinology from the University of Pennsylvania School of Medicine
	2006	John H. Erskine Lecture in Infectious Diseases, St. Jude Children’s Research Hospital Jeryl Lynn Hilleman Lecture, CDC Foundation Howard Mermelstein Lecture, Children’s Hospital of Pittsburgh The Joseph W. Mountin Lecturer, CDC Gold Medal Award from the Children’s Hospital of Philadelphia for the co-invention of RotaTeq Jonas Salk Bronze Medal from the Association for Professionals in Infection Control and Epidemiology for the co-invention of RotaTeq
	2007	Canon Ely Distinguished Professor, Boston Children’s Hospital
	2008	Stevens Distinguished Visiting Professor, LeBonheur Children’s Hospital and the University of Tennessee Medical Center Stanley A. Plotkin Award for Outstanding Achievement in Vaccines, Pediatric Infectious Diseases Society
Membership in Professional and Scientific Societies:
	National Societies:	American Society for Microbiology American Society for the Advancement of Science American Society for Virology Union of Concerned Scientists Society for Experimental Biology and Medicine The American Association of Immunologists Pediatric Infectious Disease Society Society for Mucosal Immunology The Society for Pediatric Research American Gastroenterological Association Fellow, American Academy of Pediatrics International Society for Vaccines Association for the Prudent Use of Antibiotics
	Local Societies:	Philadelphia Pediatric Society Philadelphia County Medical Society Philadelphia Childhood Immunization Coalition
	National Scientific Committees:	Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention (1998-2003) Allergy/Asthma Data Safety Monitoring Board, National Institutes for Health, National Institute for Allergy and Infectious Diseases (2005-present)
	Scientific Advisory Boards:	Vical Corporation, San Diego, CA. (2001-2003) Roy and Diana Vagelos Program in Life Sciences Management, The University of Pennsylvania American Council on Science and Health Internal Advisory Board of the Penn Center for AIDS Research
Editorial Positions:
	1987-1993	Editorial Board, Proceedings of the Society for Experimental Medicine and Biology
	1986-2001	Editorial Board, Journal of Clinical Microbiology
	1990-	Editorial Board, Virology
	1999-	Advisory Board, Child Magazine Advisory Board, PKIDS Advisory Board, Immunization Action Coalition
	2003-	Editorial Board, Infectious Diseases in Children
	2004-	Associate Editor, Human Vaccines
	2005-	Editorial Board, Clinical and Diagnostic Laboratory Immunology
	2006	Advisory Board, Every Child By Two Advisory Board, American Council on Science and Health
	2007	Advisory Board, American Baby Magazine
Academic Committees at The University of Pennsylvania:
	1989-	Member, Immunology Graduate Group Member, Molecular Biology Graduate Group
	2005-	Member, Graduate Program in Public Health Studies
	2006-	Member, Cell and Molecular Biology Graduate Group
Major Teaching and Clinical Responsibilities at The University of Pennsylvania:
	Attending Rounds in Infectious Diseases, The Children's Hospital of Philadelphia, 2 months per year Co-Director, Rotavirus Vaccine Program, The Children's Hospital of Philadelphia Course Director, Pediatric Infectious Diseases, The Children's Hospital of Philadelphia Teaching faculty, Mechanisms of Infection (ID 202) and Microbiology 100 (Vaccines), The University of Pennsylvania School of Medicine Teaching faculty, Immunobiology 404, 505, 506, 508 and 510 The University of Pennsylvania, Department of Biology Co-Director, Immunology and Cell and Molecular Biology 609 (Vaccines and Immunotherapeutics), The University of Pennsylvania
Principal Investigator of Grants:
	The study of rotaviruses with monoclonal antibodies, Individual National Research Service Award, F32 AI 06733, The National Institutes of Health, 1982-1984, $36,000. Immune protection against rotavirus infection, New Investigator Research Award, 1 R23 AI 21065, The National Institutes of Health, 1984-1987, $107,000 Protection against viral enteritis by intestinal CTLs, Biomedical Research Service Award, RR 05506-26, The Children's Hospital of Philadelphia, 1987-1989, $50,000. Protection against viral enteritis by intestinal CTLs, The Thomas B. and Jeanette E. Laws McCabe Fund, #60888, The University of Pennsylvania School of Medicine, 1987-1989, $14,000. Protection against viral enteritis by intestinal CTLs, The University of Pennsylvania Research Foundation Award, The University of Pennsylvania School of Medicine, 1988-1989, $18,000. Modification of rotavirus virulence by genetic reassortment, The Lederle Young Investigator Award in Vaccine Development, The Infectious Disease Society of America, 1988-1990, $60,000. Protection against enteric infection by intestinal CTLs, Research Career Development Award, 1 K04 AIDK00889-01 VR, The National Institutes of Health, 1989-94, $300,000. Protection against enteric infection by intestinal CTLs, R01 AI26251-01, The National Institutes of Health, 1990-95, $552,290. Rotavirus-specific cellular immune response after natural infection or immunization, Thrasher Research Fund, 1993-95, $84,168. Enhancement of rotavirus vaccine immunogenicity, World Health Organization, 1995-97, $46,000. Enhancement of viral immunogenicity by microencapsulation, R01 AI26251-06-10, The National Institutes of Health, 1995-2000, $980,350. Enhancement of bovine herpes virus glycoprotein immunogenicity by microencapsulation, Pfizer Laboratories, 1996-1997, $62,500. Enhancement of influenza virus and avian poxvirus-HIV recombinant immunogenicity by microencapsulation, Pasteur-Merieux Serum et Vaccin, 1996-1997, $230,000. Enhancement of an E. coli fimbrial protein (F11) immunogenicity by microencapsulation, Intervet Laboratories, 1996-1997, $12,000. Enhancement of canine parvovirus and feline leukemia virus immunogenicity by aqueous-based microencapsulation, Heska Laboratories, 1996-1997, $62,000. Enhancing mucosal immune responses by microencapsulation, R01 AI26251-11-15, The National Institutes of Health, 2000-2005, $1,250,000.
Lectures by Invitation (past three years):
	2006	Invited Speaker, “The Cutter Incident: How America’s First Polio Vaccine Led to the Growing Vaccine Crisis,” The Manhattan Institute, New York City, NY Invited Speaker, “Rotavirus Vaccine: Confidence Equals Protection,” “The Vaccine-Autism Myth,” 41st Annual Pediatric Postgraduate Course, Perspectives in Pediatrics, Miami Children’s Hospital, Miami, FL Invited Speaker, John H. Erskine Lecture in Infectious Diseases, “Developing a Safe Rotavirus Vaccine,” St. Jude Children’s Research Hospital, Memphis, TN Invited Speaker, 2006 Jeryl Lynn Hilleman Lecture, “Maurice Hilleman: His Extraordinary Life and Work,” 40th National Immunization Conference, Atlanta, GA Invited Speaker, “Rotavirus,” Princeton Health Care System, Princeton, NJ Invited Speaker, The Fourteenth Annual Hugh Carithers Visiting Professorship in Pediatric Infectious Diseases, Baptist Medical Center, “Vaccines and Autism,” Jacksonville, Florida Invited Speaker, American Enterprise Institute, “The Cutter Incident: A Legal Tale of Unintended Consequences for Vaccine Development,” Washington, DC Invited Speaker, “Vaccine Safety,” First Annual DC Immunization Conference, Washington, DC Invited Speaker, “Rotavirus Vaccines,” Biological Basis of Vaccine Development, Bloomberg School of Public Health, Johns Hopkins School of Medicine, Baltimore, MD Invited Speaker, Grace Kimball Memorial Lectureship, “The Cutter Incident: Lessons from the Past,” Wilkes University, Wilkes-Barre, PA Invited Speaker, Congressional Briefing on the Safety of Our Nation’s Immunization Program, Capitol Building, Washington, D.C. Invited Speaker, Immunize Nebraska: Third Annual Immunization Conference, “Vaccine Safety,” “The Rotavirus Vaccine,” Omaha, Nebraska Invited Speaker, 12th International Congress on Infectious Diseases, “Pentavalent Rotavirus Vaccine,” Lisbon, Portugal Invited Speaker, Saint Barnabas Medical Center, “Rotavirus Vaccines,” Livingston, New Jersey Invited Speaker, Public Health Association of Australia, 10th Annual Conference, “Communicating Science to the Public,” Sydney, Australia Invited Speaker, The Howard A. Mermelstein, MD Memorial Lecture, Children’s Hospital of Pittsburgh, “Rotavirus Vaccines: Is It Safe to Go Back in the Water?” Pittsburgh, PA Invited Speaker, 2006 Professional Immunization Conference, Erie County Department of Health, “Vaccines and Autism,” Erie, PA Invited Speaker, Tenth Annual Practical Review for the Clinician: Pediatric Allergy, Immunology and Infectious Diseases, Children’s Hospital of Philadelphia, “What’s New in Vaccines,” Philadelphia, PA Invited Speaker, Fourth Annual Washington Healthcare Summit, American Bar Association, “Preparing for a Public Health Crisis,” Washington, DC Invited Speaker, 2006 South Carolina Immunization Conference, “Vaccine Safety,” Columbia, SC Invited Speaker, Clinical Vaccinology Course, National Foundation of Infectious Diseases, “Autoimmune Diseases and Vaccines,” “Autism and Vaccines,” Atlanta, GA Invited Speaker, Clinical Advances in Pediatrics, Children’s Mercy Health Network, “Vaccine Safety,” “The Rotavirus Vaccine,” “Communicating Science to the Public,” Kansas City, MO Invited Speaker, The Nineteenth Annual Infectious Diseases in Children Symposium, “Vaccine Safety,” New York, NY Invited Speaker, Shots for Tots, “Vaccine Safety,” New Orleans, LA
	2007	Invited Speaker, “Pre-Licensure Clinical Trials: How Big is Big Enough?” 41st National Immunization Conference, Kansas City, MO Invited Speaker, “Maurice Hilleman: Why Don’t More People Know Him?” Emory Vaccine Dinner Club, Atlanta, GA Invited Speaker, “The Rotavirus Vaccine: From Bench to Bedside,” Eastern Society for Pediatric Research, Philadelphia, PA Invited Speaker, “Vaccines and Autism,” Charles L. Davis Foundation, West Point, PA Invited Speaker, “Vaccines and the Public: The Rotavirus Experience and Beyond,” University of Maryland School of Medicine, Baltimore, MD Invited Speaker, “The Rotavirus Vaccine,” American Society for Clinical Investigation and Association of American Physicians, Chicago, IL Invited Speaker, 9th Vaccine Update Conference, “Strategies for Effective Risk Communication,” Norfolk, VA Invited Speaker, New York Statewide Immunization Conference, “Communicating Risk: Vaccine Safety,” Cooperstown, NY Invited Speaker, Newark’s National Infant Immunization Week Leadership Banquet, “Vaccine Safety,” Newark, NJ Invited Speaker, Pediatric Academic Societies Annual Meeting, “The Rotavirus Vaccine: From Bench to Bedside,” Toronto, Ontario, Canada Invited Speaker, 2007 Northwest Immunization Conference, “Vaccine Safety,” Portland, Oregon Invited Speaker, Central Valley Immunization Conference, Childhood Immunization Coalition of Fresno/Madera Counties, “Vaccines,” Fresno, California Invited Speaker, Risk-Benefit Communication Conference, British Columbia Centre for Disease Control, “Communicating Vaccine Risks,” Vancouver, British Columbia Invited Speaker, North Carolina Medical Society, “Vaccine Safety and Perceived Risks,” Raleigh, North Carolina Invited Speaker, Iowa Department of Public Health, “The Vaccine Story,” Des Moines, Iowa Invited Speaker, Future of Pediatrics Conference, “Vaccine Safety,” Orlando, Florida Invited Speaker, International Congress of Pediatrics, “Development and Rationale for the Pentavalent Rotavirus Vaccine, Athens, Greece Invited Speaker, American Academy of Pediatrics, Alabama Chapter, 2007 Annual Meeting and Fall Pediatric Update, “Communicating Risk: Vaccines and Autism,” and “The Rotavirus Vaccine: From Bench to Bedside,” Birmingham, Alabama Invited Speaker, 14th Annual Immunize Georgia Conference, “Talking with Parents About Vaccines,” Atlanta, Georgia Invited Speaker, Distinguished Lecturer, Dr. Stephen Chartrand Memorial Pediatric Grand Rounds, Children’s Hospital, “Maurice Hilleman: His Extraordinary Life and Work,” Omaha, Nebraska Invited Speaker, American Enterprise Institute, “Vaccinated: The Quest for New Vaccines Yesterday and Today,” Washington, D.C. Invited Speaker, 2007 Got Your Shots Immunization Conference, “Vaccine Safety,” “A Brief History of Vaccines,” Minneapolis, Minnesota Invited Speaker, Grand Rounds, Rush Memorial Hospital and the University of Chicago School of Medicine, “Rotavirus Vaccines,” and Chicago Area Immunization Campaign, “Communicating Vaccine Safety Issues to Parents,” Chicago, IL Invited Speaker, “The Global Challenge of Vaccination: Legal Challenges, Ethical Conundrums,” The University of Tokyo, Tokyo, Japan
	2008	Invited Speaker, “Vaccinated: One Man’s Quest to Defeat the World’s Deadliest Diseases,” Harvard Club, Manhattan Institute, New York, NY Invited Speaker, “Communicating Science to the Public,” Maryland Partnership for Prevention, Baltimore, MD Invited Speaker, “The Rotavirus Vaccine,” Canon Ely lecture, Boston Children’s Hospital, Boston, MA Invited Speaker, “Communicating Science to the Public,” International Congress of Emerging Infectious Diseases, Atlanta, GA Invited Speaker, 42nd National Immunization Conference, “Oprah Winfrey and the Challenge of Communicating Science to the Public,” Atlanta, GA Invited Speaker, Jefferson Vaccine Center, Jefferson University Medical College, “The Cutter Incident: Lessons from the Past,” Philadelphia, PA Invited Speaker, Society for Healthcare Epidemiology of America, “Vaccines and Autism: Why Are We Still Talking about It,” Orlando, FL Invited Speaker, Stevens Distinguished Visiting Professor, “Vaccine Safety: Myth Versus Reality,” LeBonheur Children’s Hospital, University of Tennessee Medical Center, Memphis, TN Invited Speaker, “Living in the Vaccine Era: Controversy and Science,” College of Physicians of Philadelphia, Philadelphia, PA Invited Speaker, Southwest Immunization Coalition Conference, “Communicating Science to the Public,” Greensburg, PA Invited Speaker, 3rd Annual DC Immunization Conference, “Vaccine Safety,” Galludet University, Washington, DC Invited Speaker, Pediatric Academic Societies Meeting, “Vaccines and Autism Revisited: The Hannah Poling Case,” Honolulu, HI
Publications
Original Papers
Offit, P.A., G.B. Fleischer, N. Koven, and S.A. Plotkin. 1981. Severe pneumonia in Epstein-Barr virus infection. J. Adol. Health Care 2: 121-125. Offit, P.A., J. Campos, and S.A. Plotkin. 1982. Ampicillin-resistant, beta-lactamase negative, Haemophilus influenza type B. Pediatrics 69: 230-232. Offit, P.A., S. Starr, P. Zolnick, and S.A. Plotkin. 1982. Acyclovir treatment in neonatal herpes simplex virus infection. Ped. Infect. Dis. 1: 253-255. Offit, P.A., H.F. Clark, W.G. Stroop, E.M. Twist, and S.A. Plotkin. 1983. The cultivation of human rotavirus, strain 'WA', to high titer in cell culture and characterization of the viral structural polypeptides. J. Virol. Methods 7: 29-40. Offit, P.A., H.F. Clark, and S.A. Plotkin. 1983. Experimental analysis of the immune response to rotaviruses of bovine or primate origin assessed by radioimmunoassay, radioimmunoprecipitation, and plaque-reduction neutralization. Infect. Immun. 42: 293-300. Offit, P.A., Clark, H.F., M. Kornstein, and S.A. Plotkin. 1984. A murine model for oral infection with a primate rotavirus (simian strain SA-11). J. Virol. 51: 233-236. Offit, P.A., H.F. Clark, A.H. Taylor, R.G. Hess, P.A. Bachman, and S.A. Plotkin. 1984. Rotavirus-specific antibodies in fetal bovine serum and commercial preparations of serum albumin. J. Clin. Microbiol. 20: 266-270. Offit, P.A., and H.F. Clark. 1985. Protection against rotavirus-induced gastroenteritis in a murine model by passively-acquired gastrointestinal but not circulating antibodies. J. Virol. 54: 58-64. Offit, P.A., and H.F. Clark. 1985. Maternal antibody-mediated protection against gastroenteritis due to rotavirus in neonatal mice is dependent on both serotype and titer of antibody. J. Infect. Dis. 152: 1152-1158. Offit, P.A., G. Blavat, H.B. Greenberg, and H.F. Clark. 1986. Molecular basis of rotavirus virulence: role of gene segment 4. J. Virol. 57: 46-49. Offit, P.A., and G. Blavat. 1986. Identification of the two rotavirus genes determining neutralization specificities. J. Virol. 57: 376-378. Offit, P.A., R. Shaw, and H.B. Greenberg. 1986. Protection against rotavirus-induced gastroenteritis in newborn mice by monoclonal antibodies to surface proteins vp3 and vp7. J. Virol. 58: 700-703. Clark, H.F., P.A. Offit, K.T. Dolan, A. Tezza, K. Gogalin, E.M. Twist, and S.A. Plotkin. 1986. Response of adult human volunteers to oral administration of bovine and bovine/human reassortant rotaviruses. Vaccine 4: 25-31. Clark, H.F., P.A. Offit, K. Dolan, T. Furukawa, L. Bell, and S.A. Plotkin. 1985. Rotavirus (RV) of bovine and human origin: immune response of adults and children following oral administration. Pediatr. Res. 19: 290 A. Clark, H.F., T. Furukawa, L.M. Bell, P.A. Offit, P.A. Parrella, and S.A. Plotkin. 1986. Immune response of infants and children to low-passage bovine rotavirus (strain WC-3). Am J. Dis. Child. 140:350-356. Shaw, R.D., T.V. Phuoc, P.A. Offit, B.S. Coulson, and H.B. Greenberg. 1986. Antigenic mapping of the surface proteins of rhesus rotavirus. Virology 155: 434-451. Offit, P.A., G. Blavat, H.F. Clark, and H.B. Greenberg. 1986. Reassortant rotaviruses containing structural proteins vp3 and vp7 from different parents induce antibodies protective against each parental serotype. J. Virol. 60: 491-496. Bell, L.M., H.F. Clark, P.A. Offit, P.H. Slight, A.M. Arbeter, and S.A. Plotkin. 1987. Rotavirus serotype-specific neutralizing activity in human milk. Am. J. Dis. Child. 142: 275-278. Bell, L.M., H.F. Clark, E.A. O'Brien, M.J. Kornstein, S.A. Plotkin, and P.A. Offit. 1987. Gastroenteritis caused by human rotaviruses (serotype 3) in a suckling mouse model. Proc. Soc. Exp. Biol. Med. 184: 127-132. Clark, H.F., Y. Hoshino, L.M. Bell, J. Groff, P. Bachman, and P.A. Offit. 1987. A rotavirus isolate WI61 representing a presumptive new human serotype. J. Clin. Microbiol. 25: 1757-1762. Liu, M., P.A. Offit, and M.K. Estes. 1988. Identification of the simian rotavirus SA11 genome segment 3 product. Virology 163: 26-32. Offit, P.A., and K.I. Dudzik. 1988. Rotavirus-specific cytotoxic T lymphocytes cross-react with target cells infected with different rotavirus serotypes. J. Virol. 62:127-131. Offit, P.A., and K.I. Dudzik. 1989. Noninfectious rotavirus (strain RRV) induces and immune response which protects against rotavirus challenge. J.Clin. Microbiol. 27: 885-888. Matsui, S., P.A. Offit, P.T. Vo, E.R. Mackow, D.A. Benfield, R.D. Shaw, L. Padilla-Noriega, and H.B. Greenberg. 1989. Passive protection against rotavirus-induced diarrhea by monoclonal antibodies to the heterotypic neutralization domain of vp7 and the vp8 fragment of vp4. J. Clin. Microbiol. 27: 780-782. Offit, P.A., and K.I. Dudzik. 1989. Rotavirus-specific cytotoxic T lymphocytes appear at the intestinal mucosal surface after rotavirus infection. J. Virol. 63: 3507-3512. Offit, P.A., H.B. Greenberg, and K.I. Dudzik. 1989. Rotavirus-specific protein synthesis is not necessary for recognition of infected cells by virus-specific cytotoxic T lymphocytes. J. Virol. 63: 3279-3283. Offit, P.A. and Y.M. Svoboda. 1989. Rotavirus-specific cytotoxic T lymphocyte response of mice after oral inoculation with candidate rotavirus vaccine strains RRV or WC3. J. Infect. Dis. 160:783-788. Brussow H., P.A. Offit, G. Gerna, A. Bruttin, and J. Sidoti. 1990. Polypeptide specificity of anti-viral serum antibodies in children naturally infected with human rotavirus. J. Virol. 64:4130-4136. Matsuda Y., O. Nakagomi, and P.A. Offit. 1990. Presence of three P types (vp4 serotypes) and two G types (vp7 serotypes) among bovine rotavirus strains. Arch. Virol. 115:199-207. Offit, P.A. and K.I. Dudzik. 1990. Rotavirus-specific cytotoxic T lymphocytes passively protect against gastroenteritis in suckling mice. J. Virol. 64:6325-6328. Offit, P.A., S.L. Cunningham, and K.I. Dudzik. 1991. Memory and distribution of virus-specific cytotoxic T lymphocytes (CTLs) and CTLp after rotavirus infection. J. Virol. 65:1318-1324. Offit, P.A., D.B. Boyle, G.W. Both, N.L. Hill, Y.M. Svoboda, S.L. Cunningham, R.J. Jenkins, and M.A. McCrae. 1991. Surface glycoprotein vp7 is recognized by crossreactive rotavirus-specific cytotoxic T lymphocytes. Virology 184:563-568. Brussow, H., P.A. Offit, J. Sidoti. 1991. Neutralizing antibodies to heterologous animal rotavirus serotypes 5, 6, 7, and 10 in sera from Ecuadorian children. J. Clin. Microbiol. 29:869-873. Nadel, S., P.A. Offit, R. Hodinka, R. Gesser, and L.M. Bell. 1992. Upper airway obstruction in perinatally-acquired herpes simplex virus infection. J. Pediatr. 120:127-129. Offit, P.A., E.J. Hoffenberg, E.S. Pia, P.A. Panackal, and N.L. Hill. 1992. Rotavirus-specific helper T cell response in newborns, infants, children, and adults. J. Infect. Dis. 165:1107-1111. Ammari, L.K., P.A. Offit, A.B. Campbell. 1992. Unusual presentation of group B streptococcus osteomyelitis. Pediatr. Infect. Dis. J. 11:1066-1067. Offit, P.A., E.J. Hoffenberg, N. Santos, and V. Gouvea. 1993. Rotavirus-specific humoral and cellular immune response after primary, symptomatic infection. J. Infect. Dis. 167:1436-1440. Christy, C., P.A. Offit, H F. Clark, and J. Treanor. 1993. Evaluation of a bovine-human rotavirus reassortant vaccine in infants. J. Infect. Dis. 168:1598-1599. Offit, P.A., B.E.H. Coupar, Y. M. Svoboda, R.J. Jenkins, M.A. McRae, A. Abraham, N.L. Hill, D.B. Boyle, and G.W. Both. 1994. Induction of rotavirus-specific cytotoxic T lymphocytes by vaccinia virus recombinants expressing individual rotavirus genes. Virology 198:10-16. Santos, N., Riepenhoff-Talty, M., Clark, H.F., Offit, P, and Gouvea, V. 1994. Vp4 genotyping of human rotavirus in the USA. J. Clin. Microbiol. 32:205-208. Offit, P.A., Khoury, C.A., Moser, C.H., Clark, HF., and Speaker T.J. 1994. Enhancement of rotavirus immunogenicity by microencapsulation. Virology 203:134-143. Khoury, C.A., Brown, K., Kim, J., and Offit, P.A.. 1994. Rotavirus-specific intestinal immune response in mice assessed by enzyme-linked immunospot assay and intestinal fragment culture. Clin. Diag. Lab. Immunol. 1:722-728. Treanor, J.J., Clark, HF., Pichichero, M., Christy, C., Gouvea, V., Shrager, D., Pallazo, S., and Offit, P.A. 1995. Evaluation of the protective efficacy of a serotype 1 bovine-human rotavirus reassortant vaccine in infants. Pediatr. Infect. Dis. J. 14:301-307. Brown, K.A., Moser, C.A., Khoury, C.A., Kim, J.E., and P.A. Offit. 1995. Enhancement by microencapsulation of rotavirus-specific intestinal immune responses in mice assessed by enzyme-linked immunospot assay and intestinal fragment culture. J. Infect. Dis. 171:1334-1338. Khoury, C.A., Moser, C.A., Speaker, T.J., and Offit, P.A. 1995. Oral inoculation of mice with low doses of microencapsulated, noninfectious rotavirus induces virus-specific antibodies in gut-associated lymphoid tissue. J. Infect. Dis. 172: 870-874. Coffin, S.E., Klinek, M., and Offit, P.A. 1995. Induction of virus-specific antibody production by lamina propria lymphocytes following intramuscular inoculation with rotavirus. J. Infect. Dis. 172: 874-878. Moser, C.A., Speaker, T.J., Berlin, J.A., and Offit, P.A. 1996. Aqueous-based microencapsulation enhances rotavirus-specific humoral immune responses after parenteral inoculation of mice. Vaccine 14:1235-1238. Lomotan, E.A., Brown, K.A., Speaker, T.J., and Offit, P.A. 1997. Aqueous-based microcapsules are detected primarily in gut-associated dendritic cells after oral inoculation of mice. Vaccine 15:1959-1962. Moser, C.A., Speaker, T.J., and Offit, P.A. 1997. Effect of microencapsulation on immunogenicity of a bovine herpes virus glycoprotein and inactivated influenza virus in mice. Vaccine 15: 1767-1772. Coffin, S.E., Moser, C.A., Cohen, S., Clark, HF., and Offit, P.A. 1997. Immunologic correlates of protection against challenge after intramuscular immunization of mice with rotavirus. J. Virol. 71:7851-7856. Moser, C.A., Coffin, S.E., Cookinham, S., and Offit, P.A. 1998. Relative importance of rotavirus-specific effector and memory B cell responses in protection against challenge. J. Virol. 72:1108-1114. Brown, K.A. and Offit, P.A. 1998. Rotavirus-specific proteins are detected in murine macrophages in both intestinal and extraintestinal lymphoid tissue. Microbial Pathogen. 24:327-331. Coffin, S.E., and Offit, P.A. 1998. Induction of rotavirus-specific memory B cells in gut-associated lymphoid tissue after intramuscular immunization. J. Virol. 72:3479-3483. Moser, C.A., Speaker, T.J., and Offit, P.A. 1998. Effect of water-based microencapsulation on protection against EDIM rotavirus challenge in mice. J. Virol. 72:3859-3862. Coffin, S.E., Clark, S.A., Bos, N.A., Brubaker, J.O., and Offit, P.A. 1999. Migration of antigen-presenting B cells from peripheral to mucosal lymphoid tissues may induce intestinal antigen-specific IgA following parenteral immunization. J. Immunol. 163:3064-3070. Coffin, S.E., Moser, C.A., Cohen, S., Speaker, T.J., and Offit, P.A. 1999. Viral microencapsulation delays protection after intramuscular inoculation of mice with rotavirus. Drug Delivery 6:253-257. Brubaker, J., R. Patel, T.J. Speaker, and P.A. Offit. 2000. A quantitative luminescence assay for measuring cell uptake of aqueous-based microcapsules in vitro. J. Immunol. Methods 237:85-93. Macartney, K.M., D. Baumgart, S.R. Carding, J.O. Brubaker, and P.A.Offit. 2000. Primary murine small intestinal epithelial cells, maintained in long-term culture, are susceptible to rotavirus infection. J. Virol. 74:5597-5603. Brown, K.A., J.A. Kriss, C.A. Moser, W.J. Wenner, and P.A. Offit. 2000. Circulating rotavirus-specific antibody-secreting cells (ASC) predict the presence of rotavirus-specific ASC in the human small intestinal lamina propria. J. Infect. Dis. 182:1039-1043. Offit, P.A. 2000. Preventing harm from thimerosal in vaccines (correspondance). JAMA 283:2104. Moser, C.A., D.V. Dolfi, M.L. DiVietro, P.A. Offit, and H F. Clark. 2001. Hypertrophy, hyperplasia, and infectious virus in gut-associated lymphoid tissue of mice after oral inoculation with simian-human or bovine-human reassortant rotaviruses. J. Infect. Dis. 183:1108-1111. Kushnir, N., N.A. Bos, A.W. Zuercher, S.E. Coffin, C.A. Moser, P.A. Offit, and J.J. Cebra. 2001. B2 but not B1 B cells can contribute to CD4+ T cell-mediated clearance of rotavirus in SCID mice. J. Virol. 75:5482-5490. Clark, HF, D. Lawley, D. Shrager, D. Jean-Guillaume, P.A. Offit, J. Eiden, and A.R. Shaw. 2001. Immune response of infants to bovine human rotavirus serotype G1 reassortant WI79-9: the dose response pattern to virus surface protein vp7 differs from that to vp4. Vaccine [in press]. Moser, C.A. and P.A. Offit. 2001. Distribution of rotavirus-specific memory B cells in gut-associated lymphoid tissue after primary immunization. J. Gen. Virol. 82:2271-2274. Brubaker, J.O., K.K. Macartney, T.J. Speaker, and P.A. Offit. 2002. Specific attachment of covalently modified aqeous-based microcapsules to macrophages, B cells, and dendritic cells. J. Microencapsulation 19:213-223. Offit, P.A., Quarles, J., Gerber, M.A., Hackett, C.J., Marcuse, E.K., Kollman, T.R., Gellin, B.G., and Landry, S. 2002. Addressing parents’ concerns: Do multiple vaccines overwhelm or weaken the infant’s immune system? Pediatrics 109:124-129. Offit, P.A., Gerber, M.A., Hackett, C., Marcuse, E., and Gellin, B. 2002. Too many vaccines? (correspondence). Pediatrics 110:649. Offit, P.A. and Hackett, C.J. 2003. Addressing parents’ concerns: Do vaccines cause allergic or autoimmune diseases? Pediatrics 111:653-659. Chow, A.A., Moser C.A., Speaker, T.J., and Offit, P.A. 2003. Determination of efficiency of attachment of biotinylated antibodies to avidin-linked, aqueous-based microcapsules by flow cytometry. J. Immunol. Methods 2003;277:135-139. Offit, P.A., Jew, R.K. 2003. Addressing parents’ concerns: Do vaccines contain harmful preservatives, adjuvants, additives, or residuals? Pediatrics 112:1394-1401. Offit, P.A. and Coffin, S.E. 2003. Communicating science to the public: MMR vaccine and autism. Vaccine 22:1-6. Offit, P.A. and Peter G. 2003. The meningococcal vaccine: public policy and individual choices. N. Engl. J. Med. 349:2353-2356; Offit, P.A., Peter, G. Choices about meningococcal vaccine. [correspondence] N. Engl. J. Med. 2004;350:1156. Clark HF, Burke CJ, Volkin DV, Offit, P, Ward RL, Breese JS, Dennehy P, Gooch WM, Malacaman E, Matson D, Walter E, Watson B, Krah DL, Dallas MJ, Schödel F, Kaplan KM, Heaton P. 2003. Safety, immunogenicity and efficacy in healthy infants of G1 and G2 human reassortant rotavirus vaccine in a new stabilizer/buffer liquid formulation. Pediatr. Infect. Dis. J. 22:914-920. Clark HF, Lawley D, Shrager D, Jean-Guillaume D, Offit P, Eiden JJ, Bennett PS, Kaplan, KM, Shaw A. 2004. Infant immune response to human rotavirus serotype G1 vaccine candidate reassortant WI79-9: Different dose response patterns to virus surface proteins vp7 and vp4. Pediatr. Infect. Dis. J. 23:206-211. Clark HF, Bernstein DI, Dennehy P, Offit P, Pichichero M, Treanor J, Ward RL, Krah DL, Shaw A, Dallas MJ, Eiden JJ, Ivanoff N, Kaplan KM, Heaton P. 2004. Safety, efficacy, and immunogenicity of a live, quadrivalent human-bovine reassortant rotavirus vaccine in healthy infants. J. Pediatr. 144:184-190. Offit, P.A. 2005. Why are pharmaceutical companies gradually abandoning vaccines? Health Affairs Journal, 24:622-630. Offit, P.A. 2005. The Cutter Incident, 50 years later. N. Engl. J. Med. 352:1411-1412. Vesikari T, Matson DO, Dennehy P, Van Damme P, Santosham M, Rodriguez Z, Dallas MJ, Heyse JF, Gouveia MG, Black SB, Shinefield HR, Christie C, Ylitalo S, Itzler RF, Coia ML, Onorato MT, Adeyi BA, Marshall GS, Gothefors L, Campens D, Karvonen A, Watt JP, O’Brien KL, DiNubile MJ, Clark HF, Boslego JW, Offit PA, Heaton PM. 2006. Safety and efficacy of pentavalent human-bovine (WC3) reassortant rotavirus vaccine in preventing rotavirus gastroenteritis and associated healthcare contacts. N. Engl. J. Med 354:13-23. Vesikari T, Clark HF, Offit PA, Dallas MJ, DiStefano DJ, Goveia MG, Ward RL, Schödel F, Karvonen A, DiNubile MJ, Heaton PM. 2006. Effects of potency and composition of the multivalent human-bovine (WC3) reassortant rotavirus vaccine on efficacy, safety and immunogenicity in healthy infants. Vaccine 24:4821-4829.
Editorials, Reviews, Chapters:
Offit, P.A., and S.A. Plotkin. 1981. The rubella vaccine. Clin. Microbiol Newsletter 3: 130-131. Offit, P.A., and D. Rubin. 1982. Viral diseases: infections of the gastrointestinal tract. Comprehensive Therapy8: 21-26. Greenberg, H.B., P.A. Offit, C. Tran, A. Kapikian, W. Robinson, R. Shaw, R. Gaeta, and R. Bellamy. 1985. Vaccine strategies for the prevention of rotavirus diarrhea. pp. 447-455. In: S. Tzipori (ed.), Infectious diarrhea in the young: strategies for control in humans and animals Elsevier Science Publishers, Amsterdam, The Netherlands. Greenberg, H.B., and P.A. Offit. 1986. Gene coding assignments for rotavirus surface proteins. pp. 221-225. In: Development of Vaccines and Drugs against Diarrheal Diseases, Studentlitteratur, Lund, Sweden. Offit, P.A., G. Blavat, H.F. Clark, R. Shaw, and H.B. Greenberg. 1986. Role of gene segments 4 and 9 in determining rotavirus virulence and protection against rotavirus challenge. pp. 267-273, In: R.M. Chanock and R.M. Lerner (eds.): Vaccines '86: New Approaches to Immunization. Greenberg, H.B., P.A. Offit, and R.D. Shaw. 1988. Neutralization of rotaviruses in vitro and in vivo: molecular determinants of protection and role of local immunity. pp. 319-330, In: W. Strober, M.E. Lamm, J.R. McGhee, and S.P. James (eds.): Mucosal Immunity and Infections at Mucosal Surfaces. Offit, P.A. 1991. Viral gastroenteritis. In: A.M. Rudolph and J.I.E. Hoffman (eds.): Rudolph's Pediatrics, 19th Edition, Appleton and Lange, 1991: 670-671. Offit, P.A. 1993. Rotavirus. In: F.D. Burg, J.R. Ingelfinger, and E.R. Wald (eds.): Gellis and Kagan's Current Pediatric Therapy, pages 652-653. 14th Edition, W.B. Saunders. Greenberg H.B., H.F. Clark, and P.A. Offit. 1994. Rotavirus pathology and pathophysiology. Current Topics in Microbiology and Immunology, 1993;255-283, Springer-Verlag Publishers, Berlin, West Germany. Offit, P.A. 1994. Immunologic determinants of protection against rotavirus challenge. Current Topics in Microbiology and Immunology, 1993;185:229-254, Springer-Verlag Publishers, Berlin, West Germany. Clark, H F., and P.A. Offit. 1994. Rotavirus vaccines. pp. 809-822. In: S.A. Plotkin and E.A. Mortimer, Jr. (eds): Vaccines, 2nd Edition, W.B. Saunders. Offit, P.A. 1994. Virus-specific cellular immune response to intestinal infection. pp. 89-100. In: D.A.J. Tyrell and A.Z. Kapikian (eds.): Virus infections of the gastrointestinal tract, 2nd Edition, Marcel Dekker, Inc. Offit, P.A. 1994. Rotaviruses: immunological determinants of protection against infection and disease. Advances in Virus Research 44: 161-202. Offit, P.A., and Clark, HF. 1994. Rotaviruses. In: Mandell, G.L., Bennett, J.E., and Dolin, R. (eds.). Principles and Practice of Infectious Diseases, pp. 1448-1455. 4th Edition, Churchill Livingstone. Offit, P.A. and Clark, H.F. 1995. Vaccines for enteric viral pathogens. pp. 1471-8, In: Blaser, M.J., Smith, P.D., Ravdin, J.I., Greenberg, H.B., and Guerrant, R.L. (eds.). Infections of the Gastrointestinal Tract. Raven Press, New York, N.Y. Offit, P.A. Viral gastroenteritis. 1996. In: A.M. Rudolph, J.I.E. Hoffman, and C.D. Rudolph (eds.): Rudolph's Pediatrics, 20th Edition, Appleton and Lange, pp. 642-643. Conner, M.E., Estes, M.K., Offit, P.A., Clark, HF., Franco, M., Feng, N., and Greenberg, H.B. 1996. Development of a mucosal rotavirus vaccine. In: H. Kiyono, P.L. Ogra, and J.R. McGhee (eds.): Mucosal Vaccines: New Trends in Immunization, Academic Press, pp. 325-344. Offit, P.A. 1996. Host factors associated with protection against rotavirus disease: the skies are clearing. J. Infect. Dis. 174 (Suppl 1): S59-64. Clark, HF., Offit, P.A., Ellis, R.W., Eiden, J.J., Krah, D., Shaw, A.R., Pichichero, M., Treanor, J.J., Borian, F.E., Bell, L.M., and Plotkin, S.A. 1996. The development of multivalent bovine rotavirus (strain WC3) reassortant vaccine for infants. J. Infect. Dis. 174 (Suppl 1): S73-80. Clark, HF., Offit, P.A., Ellis, R.W., Krah, D., Shaw, A.R., Eiden, J.J., Pichichero, M., and Treanor, J.J. 1996. WC3 reassortant vaccines in children: brief review. Arch. Virol. [Suppl] 12: 187-198. Offit, P.A., Kapikian, A.Z., and Clark, HF. 1997. Vaccines against rotavirus. In: M.M. Levine, G.C. Woodrow, J.B. Kaper, and G.S. Cobon (eds.): New Generation Vaccines, Marcel Dekker, Inc., New York, NY, pages 659-671. Coffin, S.E., and P.A. Offit. 1997. New vaccines against mucosal pathogens: rotavirus and respiratory syncytial virus. Adv. Pediatr. Infect. Dis. 13: 333-348. Offit, P.A. 1998. Rotavirus, In: F.D. Burg, J.R. Ingelfinger, and E.R.Wald, R.A. Polin (eds.): Gellis and Kagan's Current Pediatric Therapy, pages 132-133, 14th Edition, W.B. Saunders. Offit, P.A., and H.F. Clark. 1998. The rotavirus vaccine. Current Opinion in Pediatrics, Lippincott, Williams and Wilkins, Philadelphia, Pennsylvania 11:9-13. Offit, P.A. The rotavirus vaccine. 1998. Journal of Clinical Virology 11:155-159, 1998. Clark, H F., R.I. Glass, and P.A. Offit. 1999. Rotavirus vaccines. In: S.A.Plotkin and W. Orenstein (eds): Vaccines, pages 987-1005, 3rd Edition, W.B. Saunders. Offit, P.A., and H F. Clark. 1999. Rotavirus vaccines, pp. 171-195. In: Ellis, R. (ed.): Combination Vaccines 1st Edition, Humana Press, Totowa, New Jersey. Macartney, K.K., and P.A. Offit. 2000. Immunologic methods and correlates of protection, In: Gray, J., and Desselberger, U. (eds.): Methods in Molecular Medicine: Rotaviruses, Humana Press Inc., Totawa, New Jersey [in press]. Offit, P.A. 2000. Withdrawal of rotavirus vaccine in the USA. Vaccines: Children and Practice 3:2-3. Offit, P.A. 2001. Correlates of protection against rotavirus infection and disease. In Gastroenteritis viruses. Novartis Foundation Symposium 238, pp. 106-124, Wiley, Chichester. Macartney, K.K., and P.A. Offit. How vaccine safety is monitored before and after licensure. Pediatric Annals 2001;30:392-399. Offit, P.A. 2002. The future of rotavirus vaccines. Sem Pediatr Infect Dis 2002;13: 190-195. Offit, PA, HF Clark, and RL Ward. Current state of development of human rotavirus vaccines. In: U. Desselberger and J. Gray (eds.): Viral Gastroenteritis, 2003; pp. 345-356, Elsevier Science BV, Amsterdam, The Netherlands. Clark, H F., P.A. Offit, R.I. Glass, and RM Ward. Rotavirus vaccines. In: S.A.Plotkin and W. Orenstein (eds): Vaccines, 2003; pp. 1327-1345, 4th Edition, W.B. Saunders. Offit P.A., and C.J. Hackett. Multiple vaccines and the immune system. In: S.A.Plotkin and W. Orenstein (eds): Vaccines, 2003, pp. 1583-1589, 4th Edition, W.B. Saunders. Offit, P.A. 2003. Commentary: Let’s get parents truly "fully informed" about vaccines. Contemp. Pediatr. 12-16. Offit, P.A. 2003. The power of 'box a'. Expert Rev Vaccines 2003;2:1-3. Offit, P.A. “When Judges Play Doctor,” The Wall Street Journal, February 9, 2004. Ward RL, HF Clark, PA Offit, and RI Glass. 2004. Live vaccine strategies to prevent rotavirus disease. In: M.M. Levine, J.B. Kaper, R. Rappuoli, M. Liu, and M.F. Good (eds.): New Generation Vaccines, pp. 607-620. Marcel Dekker, Inc., New York, NY. Offit, P.A. Back to the future. Expert Rev Vaccines 2004;3:89-90. Offit, P.A., Golden, J. Thimerosal and autism. Mol Psychiatry 2004;9:644. Clark HF, and P.A. Offit. Vaccine for rotavirus gastroenteritis universally needed for infants. Pediatr Ann 2004;33:536-543. Offit, P.A., and G. Peter. Meningococcal conjugate vaccine in the UK: An update. Lancet 2004;364:309-310. Offit, P.A. “The Needless Worry Over Influenza Vaccine,” The Wall Street Journal, September 14, 2004. McMillan, J.A., Abramson, J.S., Katz, S.L., and Offit, P.A. Reducing the risk of pediatric influenza: Prevention strategies help both the young and old.Contemporary Pediatrics Heaton, P.M., Goveia, M., Miller, J.M., Offit, P.A., Clark, H.F. Development of pentavalent rotavirus vaccine against prevalent serotypes of rotavirus gastroenteritis. J. Infect. Dis. 2005;192:S17-21. Offit, P.A. “Lawsuits Won’t Stop Pandemics,” The Wall Street Journal, December 1, 2005. Offit, P.A., Clark HF. A multivalent bovine-human reassortant rotavirus vaccine (RotaTeq). Pediatr Annals 2006; 35: 29-34. H.F. Clark, Offit, P.A., Plotkin, S.A., and Heaton, P.M. The new pentavalent rotavirus vaccine composed of bovine (strain WC3)-human rotavirus reassortants. Pediatr Infect Dis J 2006; 25:577-583. Offit, P.A. “Fatal Exemption,” The Wall Street Journal, January 20, 2007. Offit, P.A. “Risks of Being Risk Averse,” The Philadelphia Inquirer, July 12, 2007. Offit, P.A. “Dr. Advertising,” The New York Times, July 12, 2007. Offit, P.A. “Thimerosal and Vaccines—A Cautionary Tale,” New England Journal of Medicine 2007;357:1278-9. Offit, P.A. “Inoculated against Facts,” The New York Times, March 31, 2008. Offit, P.A. Vaccines. 2008. In: J. M. Bergelson, S. S. Shah, and T. E. Zaoutis (eds.): Pediatric Infectious Diseases, pp. 373-384. Mosby Elsevier, Philadelphia, PA.
Books:
1. Offit, P.A., and L.M. Bell. 1998. What Every Parent Should Know about Vaccines. Macmillan Press, New York, N.Y. Offit, P.A., Fass-Offit, B., and Bell, L.M. 1999. Breaking the Antibiotic Habit: A Parent’s Guide to Coughs, Colds, Ear Infections, and Sore Throats. John Wiley & Sons, New York, N.Y. Offit, P.A., and L.M. Bell. 1999. Vaccines: What Every Parent Should Know. 2nd edition, Hungry Minds, New York, N.Y. Offit, P.A., and L.M. Bell. 2003. Vaccines: What You Should Know. 3rd edition. John Wiley & Sons, New York, N.Y. Marshall, GS, Dennehy PH, Greenberg DP, Offit PA, Tan TQ. 2004. The Vaccine Handbook: A Practical Guide for the Clinician, Lippincott Williams & Wilkens, Philadelphia, PA. Offit, P.A. 2005. The Cutter Incident: How America’s First Polio Vaccine Led to a Growing Vaccine Crisis. Yale University Press, New Haven, CT Offit, P.A. 2007. Vaccinated: One Man’s Quest to Defeat the World’s Deadliest Diseases. Smithsonian Books, New York, N.Y. Offit, P.A. 2008. Autism’s False Prophets: Bad Science, Risky Medicine, and the Search for a Cure. Columbia University Press, New York, N.Y.
Educational Materials:
Informational Tear Sheet titled “The Facts about Childhood Vaccines” Videotape titled “Vaccines: Separating Fact from Fear” Videotape titled "Vaccines and your baby" Booklet titled "Vaccines and your baby" Web site (vaccine.chop.edu) of the Vaccine Education Center at the Children’s Hospital of Philadelphia. Informational Tear Sheet titled “Influenza: What You Should Know.” Informational Tear Sheet titled “Meningococcus: What You Should Know.” Informational Tear Sheet titled “Rotavirus: What You Should Know.” Informational Tear Sheet titled “Hepatitis A: What You Should Know.” Informational Tear Sheet titled “Thimerosal: What You Should Know.” Informational Tear Sheet titled “Pandemic Flu: What You Should Know.” Informational Tear Sheet titled “Shingles: What You Should Know.”
Patents:
Clark, HF., Offit, P., Plotkin, S.A. Rotavirus reassortant vaccine. United States Patent #5,626,851. Issued May 6, 1998. Speaker, T.J., Clark, H.F., Moser, C.A., Offit, P.A., Campos, M., Frenchick. P.J. Aqueous-based encapsulation of a bovine herpes virus type-1 subunit vaccine. United States Patent #6,270,800. Issued August 7, 2001. Clark HF, Speaker, T.J., Offit, P.A. Aqueous solvent encapsulation method, apparatus and microcapsules. United States Patent number 6,531,156. Issued March 11, 2003.